|
27 Feb 2026
|
Anthem Biosciences
|
BOB Capital Markets Ltd.
|
760.10
|
835.00
|
701.25
(8.39%)
|
9.85 |
Buy
|
|
|
Being one of the few backward-integrated peptide manufacturers, gives it cost edge over China competitors in GLP
|
|
14 Jul 2025
|
Anthem Biosciences
|
Deven Choksey
|
760.10
|
|
|
|
IPO Note
|
|
|
Anthem Bioscience’s initial issue is priced at 47.4x TTM EV/EBITDA
compared to peer average of 42.7x TTM EV/EVITDA. Even though, the issue
seems to be priced higher than the peer average, we believe it demands a
premium led by stronger growth, industry leading margins, steady profitability
and deep capability to produce complex products. We assign a “SUBSCRIBE”
rating to the issue.
|
|
12 Jul 2025
|
Anthem Biosciences
|
Hem Securities
|
760.10
|
|
|
|
IPO Subscribe
|
|
|
manufacturing. Company is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery,...
|
|
11 Jul 2025
|
Anthem Biosciences
|
Ventura
|
760.10
|
|
|
|
IPO Subscribe
|
|
|
|
|
10 Jul 2025
|
Anthem Biosciences
|
SBI Securities
|
760.10
|
|
|
|
IPO Subscribe
|
|
|
Anthem Biosciences Ltd. is a fast-growing innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering endto-end services across drug discovery, development and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). Serving global biotech and pharma companies, the company reached Rs 1,000 cr in revenue...
|